IPG-CANDESARTAN TABLET

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

CANDESARTAN CILEXETIL

Disponible des:

MARCAN PHARMACEUTICALS INC

Codi ATC:

C09CA06

Designació comuna internacional (DCI):

CANDESARTAN

Dosis:

32MG

formulario farmacéutico:

TABLET

Composición:

CANDESARTAN CILEXETIL 32MG

Vía de administración:

ORAL

Unidades en paquete:

30/1000

tipo de receta:

Prescription

Área terapéutica:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Resumen del producto:

Active ingredient group (AIG) number: 0135220004; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2016-08-19

Fitxa tècnica

1
PRODUCT MONOGRAPH
PR
IPG-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Date of Preparation:
August 19, 2016
Marcan Pharmaceuticals Inc.
77 Auriga Drive, Suite #4
Ottawa, Ontario
K2E 7Z7
CONTROL# 196962
2
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................................
3
SUMMARY PRODUCT INFORMATION
........................................................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................................................
3
CONTRAINDICATIONS
.................................................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................................
8
DRUG INTERACTIONS
...............................................................................................................................
14
DOSAGE AND ADMINISTRATION
..............................................................................................................
17
OVERDOSAGE
...........................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................................................
20
STORAGE AND
STABILITY..........................................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................................
23
PART II: SCIENTIFIC INFORMATION
.....................